TheraVet SA (ALVET.PA)
| Previous Close | 0.6760 |
| Open | 0.6760 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.6720 - 0.6860 |
| 52 Week Range | 0.6400 - 2.4000 |
| Volume | |
| Avg. Volume | 8,747 |
| Market Cap | 2.173M |
| Beta (5Y Monthly) | -0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
TheraVet Unveils Its Development Strategy to Address the Equine Market
GOSSELIES, Belgium, May 07, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 - Ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the deployment of its range of solutions in the highly dynamic competition horse segment.
- Business Wire
TheraVet reports Full-Year 2023 Financial Results and Provides the Preparatory Documents for the General Meeting of June 6th, 2024
GOSSELIES, Belgium, April 23, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its Full-Year results for the year to December 31, 2023.
- Business Wire
TheraVet Reports 2023 Full Year and 2024 First Quarter Revenues
GOSSELIES, Belgium, April 10, 2024--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, reports its 2023 full year and 2024 first quarter revenues.
